Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

Integration of genomic and clinical data augments surveillance of healthcare-acquired infections.

Ward DV, Hoss AG, Kolde R, van Aggelen HC, Loving J, Smith SA, Mack DA, Kathirvel R, Halperin JA, Buell DJ, Wong BE, Ashworth JL, Fortunato-Habib MM, Xu L, Barton BA, Lazar P, Carmona JJ, Mathew J, Salgo IS, Gross BD, Ellison RT.

Infect Control Hosp Epidemiol. 2019 Jun;40(6):649-655. doi: 10.1017/ice.2019.75. Epub 2019 Apr 23.

PMID:
31012399
2.
3.

Plasma Glycated CD59, a Novel Biomarker for Detection of Pregnancy-Induced Glucose Intolerance.

Ghosh P, Luque-Fernandez MA, Vaidya A, Ma D, Sahoo R, Chorev M, Zera C, McElrath TF, Williams MA, Seely EW, Halperin JA.

Diabetes Care. 2017 Jul;40(7):981-984. doi: 10.2337/dc16-2598. Epub 2017 Apr 27.

4.

Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice.

Liu F, Sahoo R, Ge X, Wu L, Ghosh P, Qin X, Halperin JA.

J Diabetes Complications. 2017 Feb;31(2):311-317. doi: 10.1016/j.jdiacomp.2016.08.021. Epub 2016 Aug 28.

5.

Role of complement and complement regulatory proteins in the complications of diabetes.

Ghosh P, Sahoo R, Vaidya A, Chorev M, Halperin JA.

Endocr Rev. 2015 Jun;36(3):272-88. doi: 10.1210/er.2014-1099. Epub 2015 Apr 10. Review.

6.

Depletion of eIF2·GTP·Met-tRNAi translation initiation complex up-regulates BRCA1 expression in vitro and in vivo.

Aktas BH, Bordelois P, Peker S, Merajver S, Halperin JA.

Oncotarget. 2015 Mar 30;6(9):6902-14.

7.

Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G.

Papadopoulos E, Jenni S, Kabha E, Takrouri KJ, Yi T, Salvi N, Luna RE, Gavathiotis E, Mahalingam P, Arthanari H, Rodriguez-Mias R, Yefidoff-Freedman R, Aktas BH, Chorev M, Halperin JA, Wagner G.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):E3187-95. doi: 10.1073/pnas.1410250111. Epub 2014 Jul 21.

8.

Synthesis of rigidified eIF4E/eIF4G inhibitor-1 (4EGI-1) mimetic and their in vitro characterization as inhibitors of protein-protein interaction.

Mahalingam P, Takrouri K, Chen T, Sahoo R, Papadopoulos E, Chen L, Wagner G, Aktas BH, Halperin JA, Chorev M.

J Med Chem. 2014 Jun 26;57(12):5094-111. doi: 10.1021/jm401733v. Epub 2014 Jun 4.

9.

Structure-activity relationship study of 4EGI-1, small molecule eIF4E/eIF4G protein-protein interaction inhibitors.

Takrouri K, Chen T, Papadopoulos E, Sahoo R, Kabha E, Chen H, Cantel S, Wagner G, Halperin JA, Aktas BH, Chorev M.

Eur J Med Chem. 2014 Apr 22;77:361-77. doi: 10.1016/j.ejmech.2014.03.034. Epub 2014 Mar 13.

10.

Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans.

Ghosh P, Vaidya A, Sahoo R, Goldfine A, Herring N, Bry L, Chorev M, Halperin JA.

J Clin Endocrinol Metab. 2014 Jun;99(6):E999-E1006. doi: 10.1210/jc.2013-4232. Epub 2014 Mar 14.

11.

3-substituted indazoles as configurationally locked 4EGI-1 mimetics and inhibitors of the eIF4E/eIF4G interaction.

Yefidoff-Freedman R, Chen T, Sahoo R, Chen L, Wagner G, Halperin JA, Aktas BH, Chorev M.

Chembiochem. 2014 Mar 3;15(4):595-611. doi: 10.1002/cbic.201300723. Epub 2014 Jan 23.

12.

Synthesis and SAR study of novel 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as potent eIF2·GTP·Met-tRNAiMet ternary complex inhibitors.

Denoyelle S, Chen T, Yang H, Chen L, Zhang Y, Halperin JA, Aktas BH, Chorev M.

Eur J Med Chem. 2013 Nov;69:537-53. doi: 10.1016/j.ejmech.2013.08.030. Epub 2013 Sep 17.

PMID:
24095748
13.

Small-Molecule targeting of translation initiation for cancer therapy.

Aktas BH, Qiao Y, Ozdelen E, Schubert R, Sevinc S, Harbinski F, Grubissich L, Singer S, Halperin JA.

Oncotarget. 2013 Oct;4(10):1606-17.

14.

A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes.

Ghosh P, Sahoo R, Vaidya A, Cantel S, Kavishwar A, Goldfine A, Herring N, Bry L, Chorev M, Halperin JA.

Am J Hematol. 2013 Aug;88(8):670-6. doi: 10.1002/ajh.23478. Epub 2013 Jun 20.

15.

Cell surface complement regulators moderate experimental myasthenia gravis pathology.

Kusner LL, Halperin JA, Kaminski HJ.

Muscle Nerve. 2013 Jan;47(1):33-40. doi: 10.1002/mus.23448. Epub 2012 Oct 5.

16.

Tumor suppression by small molecule inhibitors of translation initiation.

Chen L, Aktas BH, Wang Y, He X, Sahoo R, Zhang N, Denoyelle S, Kabha E, Yang H, Freedman RY, Supko JG, Chorev M, Wagner G, Halperin JA.

Oncotarget. 2012 Aug;3(8):869-81.

17.

DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis.

Soltys J, Halperin JA, Xuebin Q.

J Neuroimmunol. 2012 Mar;244(1-2):63-9. doi: 10.1016/j.jneuroim.2012.01.003. Epub 2012 Feb 10.

PMID:
22325826
18.

In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents.

Denoyelle S, Chen T, Chen L, Wang Y, Klosi E, Halperin JA, Aktas BH, Chorev M.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):402-9. doi: 10.1016/j.bmcl.2011.10.126. Epub 2011 Nov 16.

19.

Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target.

Chen T, Ozel D, Qiao Y, Harbinski F, Chen L, Denoyelle S, He X, Zvereva N, Supko JG, Chorev M, Halperin JA, Aktas BH.

Nat Chem Biol. 2011 Jul 17;7(9):610-6. doi: 10.1038/nchembio.613.

20.

Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.

Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA, Brown JR, Qin X.

Cancer Res. 2011 Mar 15;71(6):2298-307. doi: 10.1158/0008-5472.CAN-10-3016. Epub 2011 Jan 20.

Supplemental Content

Loading ...
Support Center